Article
Chemistry, Medicinal
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: This study compared the changes in cytokine levels in schizophrenia patients receiving atypical antipsychotics with or without metabolic syndrome. The results showed that treatment with atypical antipsychotics had different effects on inflammatory cytokine levels depending on the presence of MetS. Patients with MetS experienced increased levels of certain cytokines, while those without MetS had decreased levels of other cytokines after treatment.
Article
Psychiatry
Maria Angelaki, Eirini Alexiou, Artemis Igoumenou, Giorgos Alevizopoulos
Summary: This study investigated the type and frequency of sexual dysfunction in patients diagnosed with schizophrenia or bipolar disorder to assess the side effects of antipsychotic medications on sexual function. Only 9.1% of patients spontaneously reported sexual dysfunction. Patients treated with first-generation antipsychotics had more difficulties in achieving orgasm and decreased erection capacity, while patients treated with second-generation antipsychotics had decreased ejaculation capacity. It is important to obtain a psychosexual clinical history before initiating antipsychotic treatment to evaluate and manage sexual dysfunction induced by these medications.
FRONTIERS IN PSYCHIATRY
(2023)
Review
Clinical Neurology
Carlos Silva, Marta Rebelo, Ines Chendo
Summary: Sexual dysfunction in patients with schizophrenia is often overlooked and undertreated despite its negative impact on quality of life and medication adherence. Antipsychotic treatment is commonly perceived as a major cause of sexual impairment. Psychiatrists should actively inquire about this condition and adopt a comprehensive approach, addressing both pharmacological and non-pharmacological aspects, in managing sexual dysfunction in schizophrenia. Pharmacological strategies include adjusting the antipsychotic dose, switching to a well-tolerated antipsychotic (such as aripiprazole or brexpiprazole), and adding a coadjuvant drug (such as phosphodiesterase-5 inhibitors).
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2023)
Article
Medicine, Research & Experimental
Akitoyo Hishimoto, Norio Yasui-Furukori, Daisuke Sekine, Miyuki Matsukawa, Sakiko Yamada
Summary: This study compared the time to treatment discontinuation between patients with schizophrenia prescribed brexpiprazole (BRX) and those prescribed other atypical antipsychotics (OAA) using health insurance claims data. The results showed that patients in the BRX group were less likely to discontinue treatment and had higher treatment continuation rates compared to the OAA group.
ADVANCES IN THERAPY
(2022)
Article
Chemistry, Medicinal
Marek Krzystanek, Anna Warchala, Beata Tredzbor, Ewa Martyniak, Katarzyna Skalacka, Artur Palasz
Summary: Sexual dysfunctions in patients with schizophrenia are often severe and may be related to antipsychotic medication side effects or the illness itself. This study suggests that amantadine could be a potential treatment for improving sexual functioning in these patients.
Article
Rheumatology
Barbora Hermankova, Maja Spiritovic, Sabina Oreska, Hana Storkanova, Martin Komarc, Martin Klein, Herman Mann, Karel Pavelka, Ladislav Senolt, Jiri Vencovsky, Michal Tomcik
Summary: The study found that patients with idiopathic inflammatory myopathies (IIM) have significantly impaired sexual function, with sexual dysfunction being common and associated with symptoms such as muscle weakness, disability, and fatigue.
Article
Clinical Neurology
Linlin Sun, Nan Li, Ligang Zhang, Jingxu Chen
Summary: This study aimed to evaluate the role of Elastography point quantification (ElastPQ) in the quantitative assessment of fatty liver disease in mental disorder patients and provide a noninvasive detection method for non-alcoholic fatty liver (NAFLD) caused by atypical antipsychotics drugs (AAPDs). A total of 168 mental disorder patients treated with AAPDs and 58 healthy volunteers were included in the study. All subjects underwent ultrasound and ElastPQ tests, and the basic data of the patients were analyzed. The results showed that BMI, liver function, and ElastPQ value were significantly higher in the patient group compared to the healthy volunteers. The value of ElastPQ increased with treatment prolongation, and Olanzapine had a considerable influence on liver stiffness.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Psychiatry
Xinyu Fang, Chunying Gao, Weifeng Wu, Xiuxiu Hu, Miaomiao Shao, Chou Zhou, Renliang Cai, Jin Fang, Yi Li, Yue Xu, Xiangrong Zhang
Summary: This study explored the relationship between weight gain in schizophrenia patients with atypical antipsychotic treatment and gut microbiome. The results showed that there were no significant differences in alpha diversity between normal-weight and overweight schizophrenia patients treated with atypical antipsychotics. However, the beta diversity analysis revealed distinct clustering patterns for overweight and normal-weight patients. The composition of the gut microbiome also differed between the two groups. Function prediction identified several pathways that were significantly different between groups. Correlation analysis indicated associations between specific bacteria and BMI. Overall, these findings suggest that perturbations in the gut microbiome composition and functional pathways may contribute to weight gain in schizophrenia patients treated with atypical antipsychotics.
PSYCHIATRY RESEARCH
(2023)
Article
Endocrinology & Metabolism
Zhengyuan Chen, Xiaoqing Shao, Min He, Ming Shen, Wei Gong, Meng Wang, Yichao Zhang, Wenjuan Liu, Zengyi Ma, Zhao Ye, Yongning Lu, Nianqin Yang, Shanwen Chen, Lydia Hu, Yiming Li, Yongfei Wang, Yao Zhao, Zhaoyun Zhang
Summary: The study found that erectile dysfunction in male patients with acromegaly is associated with excessive GH and serum nitric oxide levels, while normalization of GH after treatment is beneficial for short-term recovery of erectile function.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Clinical Neurology
Vasileios Giannopapas, Dimitrios Kitsos, Anthi Tsogka, John S. Tzartos, Georgios Paraskevas, Georgios Tsivgoulis, Konstantinos Voumvourakis, Sotirios Giannopoulos, Daphne Bakalidou
Summary: This review explores possible therapeutic options for managing sexual dysfunction in people with multiple sclerosis (MS). A thorough search of the PubMed Medline database was conducted and 9 relevant records were identified. Pharmacological approaches investigated the effectiveness of sildenafil, tadalafil and onabotulinumtoxinA, while non-pharmacological interventions examined aquatic exercises, pelvic floor exercises, and the use of assistive devices, among others.
NEUROLOGICAL SCIENCES
(2023)
Article
Psychiatry
Falmata Baba Shettima, Musa Abba Wakil, Taiwo Lateef Sheikh, Mohammed Abdulaziz, Isa Bukar Rabbebe, Ibrahim Abdu Wakawa, Ogualili Placidus
Summary: The prevalence of sexual dysfunction is high among patients with schizophrenia spectrum disorders receiving antipsychotic medication. Independent correlates of sexual dysfunction include female gender, being unmarried, pseudoparkinsonism, prolactin levels, and severity of illness.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
(2023)
Review
Oncology
Bartlomiej Salata, Agnieszka Kluczna, Tomasz Dzierzanowski
Summary: Sexual disorders are common in cancer patients and often overlooked. Opioid drugs play a major role in causing sexual dysfunction, although the exact mechanisms are still being studied. Treatment options are limited and should be personalized based on the underlying pathology.
Article
Psychiatry
Brianne Redman, Chris Kitchen, Kirk W. Johnson, Padma Bezwada, Deanna L. Kelly
Summary: This study aimed to assess the prevalence of prolactin elevations, reductions in testosterone levels, sexual dysfunction symptoms, and distress in male participants taking prolactin-elevating antipsychotic medications. The results showed a high prevalence of sexual side effects, with gynecomastia in 50% and penile-related symptoms in 73% of participants. Elevated prolactin levels were found in 68% and low testosterone levels in 55% of participants, suggesting a correlation between hyperprolactinemia and low testosterone levels with sexual dysfunction symptoms in men taking antipsychotics.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Review
Andrology
Jae Joon Park, Seung Whan Doo, Allison Kwon, Do Kyung Kim, Won Jae Yang, Yun Seob Song, Sung Ryul Shim, Jae Heon Kim
Summary: Cardiovascular disease (CVD) is a major cause of sexual dysfunction, with a high prevalence rate of up to 89% in CVD patients. Pharmacotherapy is ineffective in reducing sexual problems, and sexual rehabilitation has been shown to have a broad therapeutic potential. This study indicates that sexual rehabilitation is an effective method for treating sexual dysfunction in CVD patients.
WORLD JOURNAL OF MENS HEALTH
(2023)
Review
Andrology
Jae Joon Park, Seung Whan Doo, Allison Kwon, Do Kyung Kim, Won Jae Yang, Yun Seob Song, Sung Ryul Shim, Jae Heon Kim
Summary: Cardiovascular disease is a common cause of sexual dysfunction, affecting up to 89% of patients. Ordinary treatments are not effective in relieving sexual problems, therefore sexual rehabilitation, including exercise therapy, counseling, and partner rehabilitation, is recommended. This study shows that sexual rehabilitation is effective for CVD patients with sexual dysfunction.
WORLD JOURNAL OF MENS HEALTH
(2023)